Previous Article | Next Article ![]()
Journal of Bacteriology, August 2004, p. 4931-4939, Vol. 186, No. 15
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.15.4931-4939.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Medical Microbiology and Immunology, College of Medicine, College Station, Texas 77843-1114,1 Departments of Poultry Science and Veterinary Pathobiology, Texas A&M University, College Station, Texas 77843-24722
Received 3 February 2004/ Accepted 26 April 2004
|
|
|---|
1,500 amino acid residues that can be divided into two regions based on features of the primary amino acid sequence: an N-terminal nonrepeat region followed by a repeat region composed of two types of imperfect direct amino acid repeats, called type A and type B. The repeat region bound bovine fibronectin with an affinity similar to that for the complete ShdA passenger domain, while the nonrepeat region exhibited comparatively low fibronectin-binding activity. A number of fusion proteins containing truncated fragments of the repeat region did not bind bovine fibronectin. However, binding of the passenger domain to fibronectin was inhibited in the presence of immune serum raised to one truncated fragment of the repeat region that contained repeats A2, B8, A3, and B9. Furthermore, a monoclonal antibody that specifically recognized an epitope in a recombinant protein containing the A3 repeat inhibited binding of ShdA to fibronectin. |
|
|---|
A serotype Typhimurium strain harboring a mutation in shdA is shed with the feces at reduced numbers and for a shorter period of time than its isogenic parent in a mouse model of intestinal persistence (20, 23). The recovery of the shdA mutant in reduced numbers from the feces of mice correlates with its reduced ability to colonize the murine cecum, the organ that serves as the main reservoir of luminal serotype Typhimurium in this animal model (20). Immunohistochemical analysis of cecal tissue from infected mice demonstrates that serotype Typhimurium colonizes the cecal mucosa on the epithelial brush border and at areas of epithelial erosion where the extracellular matrix is exposed to the intestinal lumen (22). ShdA is a large outer membrane protein of serotype Typhimurium that binds the extracellular matrix protein fibronectin (22). The carboxy-terminal region of ShdA (residues 1560 to 2036) shows homology with the C-terminal domains of outer membrane proteins of the autotransporter family (16, 17), including AIDA of diffuse adhering Escherichia coli (1, 2) and IcsA (VirG) of Shigella flexneri (4, 12, 25). The C-terminal domains of AIDA and IcsA are predicted to form beta barrels in the outer membrane through which an N-terminal passenger domain is transported to the bacterial surface (1, 34, 35). However, the N-terminal passenger domains of AIDA and IcsA show no sequence homology with ShdA. Flow cytometric analysis demonstrates that the surface of serotype Typhimurium can be labeled with antiserum raised against the N-terminal domain of ShdA (residues 59 to 1553), suggesting that this part of the protein is surface localized (22). Expression of ShdA in serotype Typhimurium increases binding of fibronectin to the bacterial surface (22). The passenger domain of ShdA binds in a heparin-sensitive mechanism to fibronectin at the Hep-2 domain via interaction with at least one cationic residue present on the surface of the 13FnIII repeat module that is also the binding site for the anionic polysaccharide heparin. ShdA also bound to a second heparin-binding protein, collagen I, by a heparin-sensitive mechanism, suggesting that ShdA binding activity may represent a form of molecular mimicry of heparin binding (21). Collectively, these data suggest that ShdA-mediated binding of the extracellular matrix may be a mechanism for persistent intestinal carriage of serotype Typhimurium. To further study the molecular mechanism of ShdA-mediated host-pathogen interaction, we investigated the functional regions of the ShdA passenger domain and identified a region that contains the primary fibronectin-binding site.
|
|
|---|
![]() View larger version (27K): [in a new window] |
FIG. 1. Schematic representation of the ShdA primary sequence and GST-ShdA fusion proteins used in this study. The full-length ShdA protein is shown as an arrow, and GST fusion proteins are shown as bars. The signal peptide and the C-terminal domain are predicted by sequence homology with other members of the autotransporter family (23). The passenger domain is composed of a nonrepeated region (shaded bar) and a repeat region containing three type A repeats (A), nine type B repeats (B), and intervening nonrepeated sequence (solid bar).
|
Production of immune serum. Antiserum was raised in 6-lb female New Zealand White rabbits. A prebleed (5 ml) was taken, followed by the primary immunization with a 1:1 mixture of fusion protein (0.5 mg) and Titer-Max Gold (Sigma) adjuvant (total volume, 1 ml) injected subcutaneously at >10 different locations. This procedure was repeated after 14 and 28 days. After a further 2 weeks, the rabbits were anesthetized with a Ketamine, Xylaxine, and Acepromazine cocktail and exsanguinated by cardiac puncture. The serum was prepared by standard methodology and preadsorbed with GST-glutathione Sepharose five times.
MAb development.
Production of monoclonal antibody (MAb) specific to G-S470-1553 was performed essentially as described previously (3). For primary screening of monoclonal hybridoma supernatants, ELISA plates were coated overnight with 5 µg of G-S470-1553 Tris-HCl (pH 8)/ml, and upon incubation of the hybridoma supernatants, mouse anti-ShdA was detected with a peroxidase-conjugated secondary antibody and H2O2-tetramethylbenzidine as the substrate system. Immunopositive culture wells were then submitted to a secondary screening to test for the MAb's capacity to block interaction of G-S470-1553 with fibronectin. To this end, ELISA plates were coated with fibronectin (5 µg of Tris-HCl [pH 8]/ml). The plates were washed with distilled H2O and then incubated with a mixture of the MAb and purified G-S470-1553. Binding of G-S470-1553 to fibronectin-coated wells was detected with polyclonal rabbit anti-ShdA (
-ShdA) antiserum and a peroxidase-conjugated secondary antibody as described above. The hybridomas that had lower photometric signals in this secondary screening than in a control binding assay containing no MAb were expanded, cloned by limiting dilution, and stored in liquid nitrogen for further use. Two MAbs that produced the lowest photometric signals in the binding assay were designated 3-9D 9F and 4-10A 11B, and a third that had no detectable inhibitory activity was designated 4-10G 8G. For mass production of MAb 3-9D 9F, we used a membrane-based high-density cell culture technology (CELLine 1000; Integra Biosciences, Ijamsville, Md.).
|
|
|---|
12%) acidic residues (glutamate and aspartate) out of 1,498 total residues. To further characterize fibronectin-binding activity, we first determined the time dependency of binding using an ELISA. G-S59-1553 was added to 96-well plates coated with 1 nmol of bovine fibronectin. After incubation for different time intervals, the wells were washed, and the amount of well-associated G-S59-1553 was detected with
-GST antiserum using ELISA. The amount of bound G-S59-1553 increased in a time-dependent manner for the first 60 min. Incubation of fibronectin and G-S59-1553 for >60 min did not increase the amount of G-S59-1553 bound to wells, indicating that binding equilibrium had been reached (data not shown). In all subsequent binding assays, we therefore incubated test peptides in fibronectin-coated wells for 60 min.
We next determined the concentration required for half-maximal binding at equilibrium of G-S59-1553 to bovine plasma fibronectin by using an ELISA. Increasing concentrations of G-S59-1553 were added to 96-well plates coated with 0.25 µg of bovine plasma fibronectin and incubated for 60 min. The amount of well-associated G-S59-1553 was detected with
-GST antiserum using ELISA (Fig. 2A). Saturation of binding was reached at a G-S59-1553 concentration of
3 x 107 M, and half-maximal binding occurred when the fusion protein was added to wells at a concentration of
1.2 x 107 M.
![]() View larger version (16K): [in a new window] |
FIG. 2. Binding kinetics of ShdA interaction with fibronectin. Binding of G-S59-1553 or G-S470-1553 to fibronectin (0.25 µg)-coated 96-well plates was determined by ELISA using -GST serum. G-S59-1553 (A) and G-S470-1553 (B) interactions with fibronectin were determined by incubating increasing concentrations of ligand in fibronectin-coated wells. After washes, the amount of well-associated GST fusion protein was determined using -GST antibody in an ELISA. The mean optical densities at 410 nm (OD410) from three identical wells ± standard errors are plotted.
|
100-amino-acid motif that is repeated three times. The type B repeat consists of a 60-amino-acid motif that is repeated nine times (23). To investigate whether either of these regions exhibits binding in the absence of the other, we constructed two GST fusion proteins consisting of residues 59 to 480 (G-S59-480) and 470 to 1553 (G-S470-1553) (Fig. 1). While G-S59-480 migrates in SDS-PAGE at approximately its predicted molecular mass of 70 kDa, G-S470-1553 migrated at
230 kDa, considerably higher than its predicted molecular mass of 136 kDa. This is likely due to the presence of acidic repeats in this region. The fibronectin-binding properties of these fusion proteins were compared by ELISA to those of GST and a GST fusion containing the entire ShdA passenger domain (G-S59-1553) (Fig. 3A). Binding of the nonrepeat region (G-S59-480) to fibronectin-coated wells was greater than that of GST but less than that of the entire ShdA passenger domain (G-S59-1553). In contrast, the repeat region (G-S470-1553) bound to immobilized fibronectin at a level comparable to that of the ShdA passenger domain (G-S59-1553) under these conditions.
![]() View larger version (11K): [in a new window] |
FIG. 3. Binding of ShdA passenger domain and truncated recombinant peptides. Thirty-three nanomolar G-S59-1553, G-S59-480, G-S470-1553, or GST (A) and G-S59-480, G-S480-581, G-S602-1048, G-S1086-1553, or GST (B) were incubated in wells coated with fibronectin (0.25 µg). After washes, the amount of well-associated GST fusion protein was determined using -GST antibody in an ELISA. The mean A410 values from six identical wells ± standard errors are plotted.
|
50% at 60 nM. The GST fusion protein containing the repeat region (G-S470-1553) inhibited binding at a concentration of
60 nM, and the GST fusion containing the nonrepeat region (G-S59-480) exhibited weak inhibition at a concentration of 600 nM (Fig. 4A). No inhibitory activity of GST was detectable up to 600 nM.
![]() View larger version (15K): [in a new window] |
FIG. 4. Inhibition of biotin- G-S59-1553 or biotin- G-S470-1553 binding to fibronectin by unlabeled ShdA passenger domain or truncated peptides. (A) Thirty-three nanomolar biotinylated G-S59-1553 was incubated in wells coated with fibronectin (0.25 µg) with increasing amounts of G-S59-1553 (solid triangles), GST (solid squares), G-S59-480 (solid circles), or G-S470-1553 (open circles). (B) Thirty-three nanomolar biotinylated G-S470-1553 was incubated in wells coated with fibronectin (0.25 µg) with increasing amounts of G-S480-581 (solid triangles); G-S602-1048 (open squares); G-S1086-1553 (solid circles); G-S470-1553 (open circles); a combination of G-S480-581, G-S602-1048, and G-S1086-1553 (diamonds); or GST (solid squares). In each case, biotin associated with each well following washing was determined by ELISA using streptavidin conjugated with horseradish peroxidase. The mean A410 values from six identical wells ± standard errors, expressed as percentages of values for control wells lacking added test peptides, are plotted.
|
0.75 x 107 M. Thus, the ShdA passenger domain (Fig. 2A) and the ShdA repeat region (Fig. 2B) bound fibronectin with similar affinities. Together, these data suggested that the primary fibronectin-binding domain was contained within the repeat region (residues 470 to 1553) of the ShdA passenger domain. Fibronectin-binding activity of truncated peptides derived from the ShdA repeat region. To further investigate binding of the ShdA repeat region, three additional GST-tagged fusion proteins were constructed that together contained all of the repeats present in the ShdA passenger domain. The first contained repeat A1 (G-S480-581), the second contained repeats B1 through B7 (G-S602-1048), and the third contained repeats A2, B8, A3, and B9 (G-S1086-1553) (Fig. 1). Both G-S602-1048 and G-S1086-1553 migrated at apparent molecular masses greater than their predicted molecular masses of 71 and 76 kDa, respectively, probably due to the presence of acidic repeats. None of these fusion proteins (G-S480-581, G-S602-1048, or G-S1086-1553) bound to fibronectin-coated wells at levels comparable to that of the entire repeat region (G-S470-1553) (Fig. 3B). While the GST fusion protein containing the A1 repeat (G-S480-581) exhibited a small but significant increase in binding to fibronectin-coated wells compared to the GST control, fusion proteins G-S602-1048 and G-S1086-1553 did not exhibit greater binding than GST.
In order to address the question of whether the truncated proteins were able to cooperate to bind bovine fibronectin, we tested the ability of the A1 repeat (G-S480-581), the B1 to B7 repeats (G-S602-1048), and the A2, B8, A3, and B9 repeats (G-S1086-1553) to inhibit the binding of a biotinylated GST fusion containing the repeat region of the ShdA passenger domain (biotin- G-S59-1553) to bovine fibronectin in a solid-phase binding assay (Fig. 4B) individually and in combination. The biotinylated GST fusion to the repeat region (biotin- G-S470-1553) was incubated in 96-well plates coated with bovine plasma in the presence of increasing concentrations of G-S470-1553, G-S480-581, G-S602-1048, G-S1086-1553, or GST. The GST fusion protein containing the complete repeat region (G-S470-1553) inhibited binding of biotin- G-S470-1553 to fibronectin at a concentration of 60 nM. The GST fusion proteins G-S480-581, G-S602-1048, and G-S1086-1553 and GST, individually or in combination, did not exhibit inhibitory activity (Fig. 4B). This suggested that either the fibronectin-binding sites within the repeat region overlap the truncated recombinant proteins (G-S480-581, G-S602-1048, and G-S1086-1553) and cannot function separately or the truncated proteins do not fold correctly.
Inhibition of fibronectin binding by polyclonal immune serum.
A potential limitation of measuring the binding and/or inhibitory activities of truncated peptides derived from the ShdA passenger domain is that binding activity may be affected as a result of misfolding. To overcome these potential limitations, we determined the ability of rabbit immune sera specific for the truncated peptides of ShdA to inhibit the binding of the GST fusion protein containing the ShdA passenger domain (G-S59-1553) to bovine fibronectin in a solid-phase binding assay. As a negative control, we constructed a GST fusion containing a region of the C-terminal domain of ShdA (residues 1594 to 1860), a region thought to mediate transport of the ShdA passenger domain across the bacterial outer membrane (G-S1594-1860) (Fig. 1) but not fibronectin binding. Rabbit immune sera were raised against the GST fusion proteins containing the ShdA passenger domain (G-S59-1553), repeat A1 (G-S480-581), repeats B1 to B7 (G-S602-1048), the region containing repeats A2, B8, A3, and B9 (G-S1086-1553), and the C-terminal domain (G-S1594-1860). To remove anti-GST antibodies, each serum was preadsorbed with GST bound to glutathione Sepharose resin. Following preadsorption, anti-GST antibodies were not detectable with any of the sera by Western blotting (Fig. 5). Antiserum raised against the ShdA passenger domain (
-G-S59-1553) detected GST fusion proteins containing all regions of the ShdA passenger domain but did not detect the GST fusion protein raised against the C-terminal domain (G-S1594-1860). Antiserum raised against the C-terminal domain fragment (G-S1594-1860) detected only this protein. Antisera raised against G-S480-581, G-S602-1048, and G-S1086-1553 each detected the passenger domain and the repeat region in addition to the protein used to immunize in each case. The abilities of these antisera to inhibit fibronectin binding by the ShdA passenger domain (G-S59-1553) were determined by ELISA (Fig. 6). In the presence of antiserum raised against the ShdA passenger domain (
-G-S59-1553), binding to fibronectin-coated 96-well plates was reduced to <10% of that observed in the presence of preimmune serum (Fig. 6). This indicated that antibodies in the polyclonal serum that recognized one or more epitopes of the ShdA passenger domain were able to compete with fibronectin for binding to ShdA. To further localize the positions of these epitopes, we tested the abilities of sera raised to the truncated peptides of the ShdA passenger domain to inhibit binding of the ShdA passenger domain to bovine fibronectin. Antisera raised against repeat A, repeats B1 to B7, or the C-terminal domain (
-G-S1594-1860) did not significantly decrease binding of the ShdA passenger domain (G-S59-1553) to bovine fibronectin. In contrast, the presence of antiserum raised to repeats A2, B8, A3, and B9 reduced binding to
40% of that in the presence of preimmune serum, suggesting that an important component of the ligand-binding domain may be contained in this region.
![]() View larger version (27K): [in a new window] |
FIG. 5. Reactivities of rabbit immune sera raised against G-S59-1553, G-S1594-1860, G-S480-581, G-S602-1048, G-S1086-1553, and naïve serum. The top panel shows a 4 to 15% gradient SDS-PAGE stainedwith Coomassie blue in which a total of 3 µg of purified G-S59-1553, G-S470-1553, G-S1594-1860, G-S480-581, G-S602-1048, G-S1086-1553 or GST/lane was separated. The other panels are Western blots of a 4 to 15% gradient polyacrylamide gel in which 0.15 µg of the recombinant proteins/lane was separated by SDS-PAGE. Western blots were detected with antisera raised against each recombinant protein or naïve serum (as indicate beside each panel) that was previously preadsorbed with purified GST-glutathione Sepharose. The positions of the 250-, 100-, 50-, and 25-kDa molecular mass standards (top to bottom) are indicated by horizontal bars on the left of each panel.
|
![]() View larger version (16K): [in a new window] |
FIG. 6. Inhibition of ShdA binding to fibronectin by rabbit immune sera raised to ShdA fragments. Shown is the binding of G-S59-1553 (33 nM) to wells coated with fibronectin (0.25 µg) in the presence of rabbit immune sera raised against the recombinant proteins G-S1594-1860, G-S59-1553, G-S480-581, G-S602-1048, and G-S1086-1553. Each serum was preadsorbed with GST prior to the assay. After washes, the amount of well-associated S59-1553 fusion protein was determined using -GST antibody in an ELISA. Binding is expressed as a percentage of binding in the presence of naïve serum. The mean A410 values from four identical wells ± standards errors, expressed as percentages of values for control wells lacking added test peptides, are plotted. Percentages were converted logarithmically before the calculation of statistics.
|
6 and 25%, respectively, of binding in the absence of MAb. In contrast, coincubation of MAb 4-10G 8G did not result in reduced binding of ShdA to fibronectin-coated wells (Fig. 7). The locations of epitopes recognized by each MAb were identified by expression of recombinant N-terminal GST fusion proteins containing fragments of the ShdA repeat region in E. coli and subsequent separation by SDS-PAGE. Following Western transfer, the immobilized proteins were detected with each MAb or
-GST polyclonal serum (Fig. 8A). 4-10G 8G, which did not inhibit ShdA binding, recognized an epitope in the recombinant protein containing repeats B1 to B7 and one containing repeats A2, B8, A3, and B9 but not one containing repeat A1. In contrast, 4-10A 11B and 3-9D 9F recognized an epitope present in the recombinant protein containing repeats A2, B8, A3, and B9 but not that present in repeat A1 or repeats B1 to B7 (Fig. 8A). Further analysis with recombinant proteins containing smaller fragments from the region containing repeats A2, B8, A3, and B9 indicated that 4-10A 11B and 3-9D 9F recognize distinct epitopes (Fig. 8B). 4-10A 11B recognized an epitope in the recombinant protein containing repeats A2, B8, and A3, but smaller fragments, including ones with overlapping sequence, were not recognized. In contrast, 3-9D 9F recognized all recombinant proteins containing repeat A3. Repeat A3 is a 97-residue sequence containing 16 acidic residues.
![]() View larger version (13K): [in a new window] |
FIG. 7. Inhibitory activities of MAbs on ShdA binding to fibronectin. Shown is binding of G-S59-1553 (33 nM) to wells coated with fibronectin (0.25 µg) in the presence of MAbs 4-10G 8G, 4-10A 11B, and 3-9D 9F. After washes, the amount of well-associated S59-1553 fusion protein was determined using -GST antibody in an ELISA. Binding is expressed as a percentage of binding in the absence of MAb. The mean A410 values from four identical wells ± standard errors, expressed as percentages of values for control wells lacking added test peptides, are plotted. SN, supernatant.
|
![]() View larger version (71K): [in a new window] |
FIG. 8. Epitope mapping of MAbs. Whole-cell lysates of E. coli expressing the GST fusion proteins G-S470-1553, G-S480-581, G-S602-1048, and G-S1086-1553 (A) or G-S1086-1553, G-S1086-1417, G-S1086-1186, G-S1187-1318, G-S1215-1278, G-S1319-1417, G-S1086-1278, G-S1215-1417, and G-S1319-1503 (B) were separated on 4 to 15% gradient SDS-PAGE, transferred to membranes by Western blotting, and detected with polyclonal -GST immune serum or MAb as indicated below each panel. Positive signals are indicated by arrows.
|
|
|
|---|
Here, we have investigated ShdA binding to fibronectin by a number of approaches that implicated the repeat region of the passenger domain as containing the primary ligand-binding domain. In a first approach, the repeat region of the ShdA passenger domain was implicated in fibronectin binding, since a recombinant protein containing the repeat region, but not one containing the N-terminal nonrepeat region, bound to fibronectin with similar affinity as measured by the concentration of ligand required to achieve half-maximal binding at equilibrium (
100 nM in each case). These data were supported by the observation that the repeat region, but not the nonrepeat region, was able to inhibit binding of the passenger domain to fibronectin. It was not possible to calculate the dissociation constant for the ShdA interaction with fibronectin. However, it is important to note that the reported concentration at which half-maximal binding at equilibrium was observed is likely an underestimate, since the recombinant fusion proteins used in this study were prone to degradation during expression in the E. coli host. This degradation could not be reduced by expression in protease-negative strains (data not shown). Since we found that the truncated peptides of the repeat region did not retain binding activity, it is likely that only the full-length protein contributed to binding in the assays reported here (21, 38).
The repeat region has an estimated molecular mass of
100 kDa and consists of 1,073 residues, the majority of which are components of either type A or type B repeated sequence modules. Since smaller recombinant proteins containing fragments of the repeat region did not retain the ability to bind fibronectin, it seems unlikely that fibronectin binds a simple linear sequence within ShdA. Rather, it is likely that a relatively large region of ShdA, when folded correctly, is required for the ligand-binding domain to adopt the appropriate conformation. A similar situation has been described for the invasin protein of Yersinia pseudotuberculosis, whose binding to ß1 integrins requires a minimal region consisting of 192 residues of a C-terminal domain for molecular mimicry of fibronectin binding of ß1 integrins (24). However, the absence or incorrect folding of neighboring domains had no measurable effect on ligand binding of recombinant invasin using in vitro binding assays. Invasin molecular mimicry of fibronectin ß1 integrin binding is dependent on three key residues that have identical separations in both fibronectin and invasin. The crystal structure model of invasin demonstrates that the three key residues of invasin (Asp811, Asp911, and Arg863), which are distantly separated on the primary amino acid sequence, are present in different protruding loops on the carboxyl-terminal domain (15). The precise conformation of the loops, and therefore the key residues, is heavily dependent on correct folding of the domain. The repeat region of ShdA may also form a single domain that when correctly folded has one or more binding sites for fibronectin.
Our second approach to study ShdA binding to fibronectin involved the use of ShdA-specific polyclonal antibodies or MAbs. The fact that only polyclonal serum raised against either the entire ShdA passenger domain or a recombinant protein containing A2, B8, A3, and B9 was capable of inhibiting ShdA binding to fibronectin was the first indication that the repeats A2, B8, A3, and B9 contained important components of the ligand-binding domain. Furthermore, of three ShdA-specific MAbs, the epitopes recognized by the two MAbs that inhibited ShdA binding (3-9D 9F and 4-10A 11B) were mapped to the A2-B8-A3 repeats, while the MAb (4-10G 8G) with no inhibitory activity was mapped to an epitope present in the B1 to B7 repeats. That 4-10A 11B was unable to recognize overlapping recombinant proteins smaller than A2-B8-A3 suggested that this MAb recognized an epitope not present in these truncated peptides, presumably due to misfolding. However, 3-9D 9F recognized all recombinant proteins containing the A3 repeat, suggesting that the sequence in this part of the correctly folded ShdA repeat region contributes an exposed surface, binding to which inhibits interaction with fibronectin either by directly competing for a binding site or by steric hindrance. ShdA binds one or more basic amino acids that form a cationic cradle in the Hep-2 domain of fibronectin via electrostatic forces (21). It therefore seems likely that acidic residues in the ShdA ligand-binding domain are involved in this interaction. The A3 repeat is composed of 97 residues, of which 16 have acidic side chains (aspartate or glutamate). Since the cationic cradle of the fibronectin Hep-2 domain forms a continuous patch of positive charge contributed from six surface-exposed basic residues, it seems likely that several acidic residues from repeat A3, and potentially other residues from elsewhere in the ShdA passenger domain, may contribute to binding.
That the repeat region alone is necessary and sufficient for maximal fibronectin binding in vitro raises a question as to the function of the nonrepeat region. The nonrepeat region consists of 421 residues with a predicted molecular mass of 42 kDa that contain no common sequence motifs and exhibit no amino acid homology with sequences in the available databases. It is possible that the nonrepeat region has a second activity unrelated to that of the fibronectin domain of the repeat region. A multidomain and multifunctional character has been described for a number of bacterial outer surface proteins. For example, the FnbpA protein of S. aureus has multiple fibronectin-binding motifs in an extended carboxy domain and fibrinogen-binding activity in a globular domain in the N-terminal domain (33, 36). These binding activities are completely independent, since fragments containing only one domain retain maximal binding activity for its cognate receptor (26). Another possibility is that the nonrepeat region of ShdA, while not directly participating in fibronectin binding in vitro, may nonetheless be required for either secretion or correct presentation of the ligand-binding domain (repeat region) on the bacterial cell surface and thus may be required to facilitate interaction with fibronectin or other ligands during natural infections.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»